ReviewJournal of neuro-oncology2018
Tumor treating fields: a new approach to glioblastoma therapy.
Review in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.Journal of neuro-oncology · 2020Pooled it
- The Preclinical Effects and Mechanisms of Biofield Therapy on Pancreatic Cancer Cell Growth and Metastasis.Cancer medicine · 2026Article
- Review
- Our clock is truly ticking-a qualitative study on patients' experiences of tumor treating fields.Neuro-oncology practice · 2025Article
- Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.Journal of neuro-oncology · 2024Article
- Glioma Stem Cells-Features for New Therapy Design.Cancers · 2024Review
- Neurooncological Rehabilitation in Diffuse Gliomas.Cureus · 2024Article
- Engineered smart materials for RNA based molecular therapy to treat Glioblastoma.Bioactive materials · 2024Article
- Review
- Review
- RNA modification patterns based on major RNA modifications define tumor microenvironment characteristics in glioblastoma.Scientific reports · 2022Article
- RNA methylation in mammalian development and cancer.Cell biology and toxicology · 2021Review
- Multiple subtentorial metastasis in diffuse midline glioma receiving tumor treating fields: a case report and literature review.Annals of translational medicine · 2021Article
- The adaptive transition of glioblastoma stem cells and its implications on treatments.Signal transduction and targeted therapy · 2021Review
- Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.AAPS PharmSciTech · 2021Review
- Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [Neoplasia (New York, N.Y.) · 2021Article
- Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.Cancers · 2020Review
- Article
- Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma.Frontiers in oncology · 2020Review
- Formin-like 1 (FMNL1) Is Associated with Glioblastoma Multiforme Mesenchymal Subtype and Independently Predicts Poor Prognosis.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is an aggressive brain malignancy with poor outcomes. Current standard of care involves surgery, radiotherapy and chemotherapy. Even with optimal treatment, 5-year survival rates are low. Many patients are unable to tolerate the considerable side effects that therapy involves and suffer from low quality of life. Anti-mitotic tumor treating fields have shown potential in treating glioblastoma with data suggesting that they prolong disease-free survival and overall survival. Novocure has marketed a device that generates these fields via externally placed electrodes. Incorporation of electric field therapy into GBM treatment has been somewhat slow, due to concerns about cost, practicality of its usage from a patient perspective, and hesitation of the medical and scientific community to embrace its unconventional mechanism. However, clinical trials have demonstrated this therapy has relatively minor side effects and high patient compliance. In this review, we explore the current state of this technology and discuss the benefits and limitations of tumor treating fields.
Indexed as
Identifiers
29349613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.